Scarica l'app Stockscreener
0.7675
2.23%
-0.0175
Dopo l'orario di chiusura:
.76
-0.0075
-0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRBU Giù?
Forum
Previsione
Precedente Chiudi:
$0.785
Aprire:
$0.7411
Volume 24 ore:
1.01M
Relative Volume:
0.83
Capitalizzazione di mercato:
$71.38M
Reddito:
$34.48M
Utile/perdita netta:
$-102.07M
Rapporto P/E:
-0.5257
EPS:
-1.46
Flusso di cassa netto:
$-104.90M
1 W Prestazione:
-18.27%
1M Prestazione:
-30.23%
6M Prestazione:
-58.96%
1 anno Prestazione:
-83.09%
Intervallo 1D:
$0.7008
$0.784
Intervallo di 1 settimana:
$0.7008
$0.9431
Portata 52W:
$0.7008
$4.665
Caribou Biosciences Inc Stock (CRBU) Company Profile
Nome
Caribou Biosciences Inc
Settore
Industria
Telefono
510-982-6030
Indirizzo
2929 7TH STREET, SUITE 105, BERKELEY
Confronta CRBU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
0.7675 | 71.38M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Iniziato | Evercore ISI | Outperform |
| 2023-07-11 | Iniziato | Truist | Buy |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-17 | Iniziato | BofA Securities | Buy |
| 2021-08-17 | Iniziato | Citigroup | Neutral |
| 2021-08-17 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Caribou Biosciences Inc Borsa (CRBU) Ultime notizie
Caribou Biosciences stock hits 52-week low at $0.71 By Investing.com - Investing.com South Africa
Caribou Biosciences stock hits 52-week low at $0.71 - Investing.com Australia
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - Markets Insider
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts - Defense World
Caribou Biosciences stock hits 52-week low at $0.95 By Investing.com - Investing.com Canada
Caribou Biosciences stock hits 52-week low at $0.95 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation - Markets Insider
Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out - Markets Insider
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture - Investing.com Canada
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture By Investing.com - Investing.com South Africa
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19 - Marketscreener.com
US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect - Markets Insider
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock By Investing.com - Investing.com Australia
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock - Investing.com India
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates - MSN
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in its Shares - Markets Insider
Caribou Biosciences stock hits 52-week low at $1 By Investing.com - Investing.com Australia
Caribou Biosciences stock hits 52-week low at $1 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
CRBU FY2029 EPS Reduced by Brookline Capital Management - Defense World
Caribou Biosciences Brass Face Investor's Clinical Trials Suit - Law360
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GuruFocus.com
Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation - Markets Insider
RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk - Marketscreener.com
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Caribou Biosciences reports Q4 EPS (39c), consensus (42c) - TipRanks
Caribou Biosciences shares rise on narrower-than-expected Q4 loss By Investing.com - Investing.com Australia
Caribou Biosciences shares rise on narrower-than-expected Q4 loss - Investing.com India
Caribou Biosciences, Inc. SEC 10-K Report - TradingView
Caribou Biosciences, Inc. Anticipates Clinical Data from CB-010 and CB-011 in H1 2025 Amidst Advancements in Hematologic Malignancies and Autoimmune Disease Therapies - Nasdaq
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - The Bakersfield Californian
Caribou Biosciences, Inc. Sued for Securities Law ViolationsI - GuruFocus.com
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Caribou Biosciences Leaders Overhyped Cancer Therapy, Suit Says - Bloomberg Law News
Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts - Defense World
Institutional investors may adopt severe steps after Caribou Biosciences, Inc.'s (NASDAQ:CRBU) latest 13% drop adds to a year losses - Simply Wall St
Caribou Biosciences Inc Azioni (CRBU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):